Rat Her2 / ErbB2 Protein, Tag Free (MALS verified)

제품 번호/규격
가격
Availability
수량
HE2-R5213-100ug
$360.00
In Stock - Delivery in 1-2 business days
HE2-R5213-1mg
$2,380.00
In Stock - Delivery in 2 weeks
HE2-R5213
제품 금액 :
$ 0
신제품 제안 Request Quote
Contact Us
Contact Us
제품 금액:
$ 0
  • 제품 세부정보
  • 데이터 표시
  • Reviews & Citations
  • Important Statement
  • Resources
Synonyms

ERBB2, CD340, HER-2, neu, HER2, MLN19, NEU, NGL, TKR1

Source

Rat Her2 Protein, Tag Free (HE2-R5213) is expressed from human 293 cells (HEK293). It contains AA Thr 26 - Thr 656 (Accession # AAH61863.1).

Predicted N-terminus: Thr 26

Molecular Characterization

This protein carries no "tag".

The protein has a calculated MW of 69.7 kDa. The protein migrates as 70 kDa and 80-95 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin

Less than 1.0 EU per μg by the LAL method / rFC method.

Purity

>95% as determined by SDS-PAGE.

>90% as determined by SEC-MALS.

Formulation

Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

Reconstitution

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Shipping and Storage

This product is shipped at ambient temperature.

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:
  • -20°C to -70°C for 12 months in lyophilized state;
  • -70°C for 3 months under sterile conditions after reconstitution.

배경 소개

Human Epidermal Growth Factor Receptor 2 (HER2), also known as ErbB-2, is a cell membrane-bound receptor tyrosine kinase of the EGFR/ErbB family, encoded by the ERBB2 gene. It is crucial for cell growth and differentiation signaling. Uniquely, HER2 is an orphan receptor lacking a direct ligand, but forms highly active heterodimers with other ligand-bound ErbB family members, significantly amplifying oncogenic signals.
Aberrant amplification or overexpression of the HER2/neu proto-oncogene is a key oncogenic driver. In breast cancer, approximately 25-30% of patients exhibit HER2 overexpression, leading to a more aggressive disease phenotype with faster growth, increased metastasis, and often reduced chemotherapy sensitivity. This correlates with poorer prognosis and makes HER2 a critical prognostic, predictive biomarker, and a major therapeutic target.